{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:49:20Z","timestamp":1777654160852,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jdcr.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T07:29:08Z","timestamp":1684135748000},"page":"49-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Targeted therapy with ixekizumab in\u00a0pyoderma gangrenosum: A case series and\u00a0a\u00a0literature overview"],"prefix":"10.1016","volume":"37","author":[{"given":"Andrew S.","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redina","family":"Bardhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-2894","authenticated-orcid":false,"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2023.05.002_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2008","article-title":"Effective strategies for the management of pyoderma gangrenosum: a comprehensive review","volume":"95","author":"Patel","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.05.002_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum","volume":"173","author":"Caproni","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.05.002_bib3","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjd.15837","article-title":"Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum","volume":"178","author":"Ortega-Loayza","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2023.05.002_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15716","article-title":"Successful treatment of cabozantinib-induced pyoderma gangrenosum with ixekizumab therapy: a case report","volume":"35","author":"Kao","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdcr.2023.05.002_bib5","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jdcr.2023.05.002_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.jdcr.2023.05.002_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdcr.2023.05.002_bib8","article-title":"Pyoderma gangrenosum treated with secukinumab: a case report","volume":"8","author":"McPhie","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"12","key":"10.1016\/j.jdcr.2023.05.002_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15910","article-title":"Off-label uses of ustekinumab","volume":"35","author":"Ye","year":"2022","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jdcr.2023.05.002_bib10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.14809","article-title":"Anakinra for recalcitrant pyoderma gangrenosum","volume":"46","author":"O\u2019Connor","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.jdcr.2023.05.002_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jdcr.2020.08.033","article-title":"Rapid resolution of pyoderma gangrenosum with brodalumab therapy","volume":"6","author":"Tee","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.jdcr.2023.05.002_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","article-title":"Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab","volume":"6","author":"Petty","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"9","key":"10.1016\/j.jdcr.2023.05.002_bib13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jdcr.2023.05.002_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jdcr.2023.05.002_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaad.2020.04.010","article-title":"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors","volume":"83","author":"Wright","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:12Z","timestamp":1762475112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"alternative-id":["S2352512623001509"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.002","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy with ixekizumab in\u00a0pyoderma gangrenosum: A case series and\u00a0a\u00a0literature overview","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}